Back

Real-world results of selexipag in treating pulmonary hypertension in a portuguese population

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: ePosters in valvular and pulmonary 4 Pulmonary Hypertension HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Joana Mesquita Guimaraes

University Hospitals of Coimbra, Coimbra (Portugal)

3 More presentations in this session

Presentation thumbnail
Exploring the clinical relevance of TSAT <21% as an iron deficiency indicator in pulmonary arterial hypertension: a comparative analysis with alternative criteria and existing guidelines
Doctor N. Ilchyshyn (Almada, PT)
Abstract Slides Video
Presentation thumbnail
Long-term survival outcomes and baseline hemodynamics in patients with PAH versus CTEPH
Doctor J. Mesquita Guimaraes (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
HFWM: exploring biomarkers in chronic thromboembolic pulmonary hypertension (CTEPH): prognostic significance, and post-PEA dynamics analysis
Doctor A. Cuomo (Naples, IT)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in valvular and pulmonary 4

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Efficacy and tolerability of triple sequential combination therapies with selexipag in patients with pulmonary arterial hypertension : insights from a single-centre study
thumbnail
Congress Presentation
Evaluation of patients engagement with a digital intervention for daily disease management in pulmonary arterial hypertension
thumbnail
Congress Presentation
Effects of beta blockers on outcome in patients with PAH with and without comorbid conditions: a Multicenter Prospective Cohort Study (BNP-PL).

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources